Celcuity (CELC) Stock Price, News & Analysis

Company Overview

Celcuity, Inc. is a clinical-stage biotechnology company that develops functional diagnostic tests designed to help identify patients who may benefit from targeted cancer therapies. The company’s technology is intended to measure the activity of cellular signaling networks in living tumor cells, rather than relying solely on the presence or absence of individual biomarkers.

Celcuity’s proprietary CELsignia platform analyzes patient tumor samples to identify abnormal signaling activity associated with cancer growth and treatment response. The company is developing CELsignia diagnostic tests for use in oncology, including applications involving breast cancer and signaling pathways such as HER2 and PI3K. These tests are intended to support more personalized treatment decisions and may help identify patients whose tumors could respond to targeted therapies.

Based in Minneapolis, Minnesota, Celcuity works with biopharmaceutical companies and clinical research organizations to evaluate its platform and potential diagnostic applications. The company was founded by Brian Sullivan, who serves as its chief executive officer. Its products and services remain focused primarily on research, clinical development and the advancement of precision oncology diagnostics.

Key Stats

• Today's Range: $75.00 to $75.00
• 50-Day Range: $72.10 to $96.43
• 52-Week Range: $45.03 to $151.02
• Volume: 7,850 shs
• Average Volume: 1.07 million shs
• Market Capitalization: $3.56 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $154.25
• Consensus Rating: Moderate Buy

Celcuity Stock Analysis - MarketRank™

Celcuity scored higher than 57% of companies evaluated by MarketBeat, and ranked 381st out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Celcuity has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Celcuity has a consensus price target of $154.25, representing about 109.5% upside from its current price of $73.62.

Amount of Analyst Coverage

Celcuity has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Celcuity are expected to grow in the coming year, from ($4.82) to ($2.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Celcuity is -17.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Celcuity is -17.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Celcuity has a P/B Ratio of 33.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.79% of the float of Celcuity has been sold short.

Short Interest Ratio / Days to Cover

Celcuity has a short interest ratio ("days to cover") of 12.48, which indicates bearish sentiment.

Change versus previous month

Short interest in Celcuity has recently increased by 6.29%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Celcuity does not currently pay a dividend.

Dividend Growth

Celcuity does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.12

News Sentiment

Celcuity has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Celcuity this week, compared to 6 articles on an average week.

Search Interest

10 people have searched for CELC on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.

MarketBeat Follows

4 people have added Celcuity to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Celcuity insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.33% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CELC
• CIK: 1603454
• Web: www.celcuity.com
• Phone: (763) 392-0767
• Fax: N/A
• Employees: 155
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Celcuity: $154.25
• High Price Target: $178.00
• Low Price Target: $110.00
• Potential Upside/Downside: +109.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$177.04 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -350.78%
• Return on Assets: -41.54%

Debt

• Debt-to-Equity Ratio: 6.04
• Current Ratio: 8.93
• Quick Ratio: 8.93

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.17 per share
• Price / Book: 33.99

Miscellaneous

• Outstanding Shares: 48,932,000
• Free Float: 42,409,000
• Market Cap: $3.61 billion
• Optionable: Optionable
• Beta: 0.10